Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.
Nicola RiccettiMaria BlettnerKatherine J TaylorBeatrice WehlerBernhard GohrbandtUrsula NestleRobert BalsMarcus StockingerThomas WehlerSusanne SingerMartin EichlerPublished in: Journal of cancer research and clinical oncology (2022)
Our results suggest that the specific side effects of TKI therapy can impair QOL among lung cancer survivors. Therefore, specific focus towards the optimal management of these side effects should be considered.